Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
On Monday, Vincerx Pharma Inc (NASDAQ:VINC) presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research Annual Meeting 2024.
周一，Vincerx Pharma Inc（纳斯达克股票代码：VINC）在美国癌症研究协会2024年年会上公布了 VIP236 的初步第一阶段数据和研发进展的最新情况。
VNC-236-101 is a Phase 1 dose-escalation study with monotherapy VIP236 for metastatic tumor patients who have exhausted all standard therapy options.
VNC-236-101 是一项 1 期剂量递增研究，采用单一疗法 VIP236，适用于已用尽所有标准疗法的转移性肿瘤患者。
- Fifteen patients have been dosed to date on the once-every-three-weeks (Q3W) schedule:
- The Q3W schedule is well tolerated with no dose-limiting toxicity (DLT) in any patients, and no patients have discontinued VIP236 due to an adverse event.
- No severe or life-threatening diarrhea has been observed, validating the purposeful design of VIP236's optimized camptothecin payload.
- Seven patients have achieved objective stable disease, including tumor reduction. Four patients remain on the study, with the longest-treated patient for 168 days.
- 迄今为止，已按照每三周一次（Q3W）的时间表给15名患者服药：
- Q3W 计划耐受性良好，对任何患者均无剂量限制毒性 (DLT)，也没有患者因不良事件停药 VIP236。
- 没有观察到严重或危及生命的腹泻，这验证了 VIP236 优化的喜树碱有效载荷的有针对性的设计。
- 七名患者实现了客观稳定的疾病，包括肿瘤减少症。四名患者仍在研究中，接受治疗时间最长的患者为168天。
VNC-943-101 is a Phase 1 dose-escalation study with monotherapy VIP943 for CD123+ acute myeloid leukemia, B-cell acute lymphocytic leukemia, or myelodysplastic syndromes.
VNC-943-101 是一项 1 期剂量递增研究，采用单一疗法 VIP943 治疗 CD123+ 急性髓系白血病、B 细胞急性淋巴细胞白血病或骨髓增生异常综合征。
- VIP943 is administered once per week.
- No DLTs occurred in Cohort 1 and 2. Four patients have been enrolled in Cohort 3 (0.7 mg/kg) and are undergoing DLT assessment.
- VIP943 PK data shows very little free payload in circulation, consistent with the favorable safety profile observed preclinically and clinically.
- VIP943 每周给药一次。
- 队列 1 和 2 中未发生 DLT。四名患者已加入队列3（0.7 mg/kg），并正在接受DLT评估。
- VIP943 PK数据显示，流通中的自由有效载荷很少，这与临床前和临床观察到的良好安全性相一致。
Vincerx will present additional Phase 1 data for VIP236 and VIP943 on or around the 2024 European Hematology Association Annual Meeting in June 2024.
Vincerx 将在 2024 年 6 月的 2024 年欧洲血液学协会年会上或前后公布 VIP236 和 VIP943 的其他 1 期数据。
Vincerx also reported preclinical experiments applying the next-generation effector chemistry of its VersAptx platform to the antibodies of approved antibody-drug conjugates (ADCs), Trodelvy and Enhertu, demonstrating the potential to improve tumor toxicity of ADCs by orders of magnitude.
Vincerx还报告了将其VersaptX平台的下一代效应化学应用于已批准的抗体药物偶联物（ADC）Trodelvy和Enhertu的抗体的临床前实验，表明ADC的肿瘤毒性有可能提高几个数量级。
- In in vitro tumor models, Vincerx's sacituzumab-legumain-KSPi ADC had a 20-fold improvement in tumor toxicity compared with Trodelvy (sacituzumab-govitecan).
- The company's trastuzumab-legumain-KSPi ADC demonstrated an 8-fold increase in tumor toxicity compared with Enhertu (fam-trastuzumab-deruxtecan).
- 在体外肿瘤模型中，与Trodelvy（sacituzumab-govitecan）相比，Vincerx的Sacituzumab-Legumain-KSPI ADC的肿瘤毒性提高了20倍。
- 该公司的Trastuzumab-Legumain-KSPI ADC显示，与Enhertu（fam-trastuzumab-deruxtecan）相比，肿瘤毒性增加了8倍。
Price Action: VINC shares are down 73.30% at $1.27 on the last check Tuesday.
价格走势：在周二的最后一次支票中，VINC股价下跌73.30％，至1.27美元。
Photo via Shutterstock
照片来自 Shutterstock